The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Offer and Placing Update

18 Sep 2020 16:14

RNS Number : 4858Z
Adamas Finance Asia Limited
18 September 2020
 

18 September 2020

ADAMAS FINANCE ASIA LIMITED

("ADAM" or the "Company")

Open Offer and Placing Update

 

The Company announces that further to the announcement on 10th September 2020 there has been a further delay in the receipt of the remaining subscription monies due under the Placing. To date, approximately 60% of the committed subscription monies have been received by the Company, with one placee's commitment remaining outstanding. The Company is in contact with the placee and understands the delay is logistical only. The Company is therefore expecting to receive these outstanding subscription monies shortly, and in any event by no later than the 30th of September 2020. The Company will not extend the timetable past this date and should the outstanding subscription monies not be received by such date, it will take the necessary steps to close the Open Offer and Placing forthwith.

 

Consequently, and as a change to the timetable initially set out in the Company's announcement and Circular on 17th July 2020 and further to the announcement of 10th September 2020, application has been made for the Placing, Open Offer and Placing Commission Shares totalling 13,165,782 New Ordinary Shares to be admitted to trading on AIM on 7th October 2020 ("Admission"). CREST members' accounts will be credited in respect of the New Ordinary Shares in uncertificated form as soon as possible after 8.00 a.m. on 7th October 2020 and dispatch of share certificates in respect of the New Ordinary Shares in certificated form (certificated holders only) is expected to occur by approximately 14th October 2020.

 

As a result of the current change to the Placing and Open Offer timetable and further to the Company's announcements of 5th August 2020, 7th September and 10th September 2020, the timing for the Company's name change taking effect will occur as soon as practicable after the Placing and Open Offer has been completed.

 

Upon Admission the Company's issued share capital (excluding 2,647,804 shares held in Treasury by the Company) will then consist of 115,590,204 Ordinary Shares. All of the shares, excluding those in Treasury, have equal voting rights. The Company's total issued share capital (including those now held in Treasury) comprises 118,238,008 Ordinary Shares. This figure of 115,590,204 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The Company has also considered a contingency to close the Placing at a lower subscription amount and pursue all of its rights under existing legal agreements should all subscription monies not be received by the 30th of September 2020. Should the Company pursue this contingency a further announcement will be made with respect to a further revision to the Placing and Open Offer timetable.

 

Full details of the Open Offer and Placing are available in the Circular, published on 17th July 2020 and posted to Qualifying Shareholders. The Circular is also available on the Company's website at http://adamasfinance.com.

 

Capitalised terms used in this announcement have the meanings given to them in the announcement made and circular published on 17th July 2020 unless the context provides otherwise.

 

For further information on ADAM, please visit the Company's website at http://adamasfinance.com and follow the Company on Twitter (@AdamasFinance).

 

 

 

 

 

 

 

 

 

 

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Adamas Finance Asia Limited

+44 (0) 778 531 5588

John Croft

WH Ireland Limited - Nominated Adviser

+44 (0) 20 7220 1666

James Joyce

James Sinclair Ford

Pello Capital Limited - Corporate Broker

+44 (0) 20 3700 2500

Mark Treharne

Maitland/AMO - Communications Advisor

+44 (0) 20 7379 5151

James Benjamin

Peter Hamid

 

About Adamas Finance Asia

Adamas Finance Asia Limited (ADAM) is quoted on the AIM Market of the London Stock Exchange and is committed to providing shareholders with attractive uncorrelated, risk adjusted long-term returns from a combination of realising sustainable capital growth and delivering dividend income.

 

The Company is focused on providing growth capital and financing to emerging and established Small and Medium Enterprises (SME) sector throughout Asia, well diversified by national geographies, instruments and asset classes. This vital segment of the economy is underserved by the traditional banking industry for regulatory and structural reasons.

 

The Company's investment manager, Harmony Capital, seeks to capitalise on its team's established investment expertise and broad networks across Asia. Through rigorous diligence and disciplined risk management, Harmony Capital is dedicated to delivering attractive income and capital growth for shareholders with significant downside protection through selectively investing in assets and proactively managing them.

 

Harmony Capital is predominately sourcing private opportunities and continues to create a strong pipeline of attractive income generating assets from potential investments in growth sectors across Asia, including healthcare, fintech, hospitality, IT and property. 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUWGBUPUGAR
Date   Source Headline
24th Oct 201810:24 amRNSNet Asset Value Update
16th Oct 201810:34 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
17th Aug 201811:43 amRNSResult of AGM
13th Aug 201810:50 amRNSNet Asset Value Update
26th Jul 201812:06 pmRNSNet Asset Value Update
23rd Jul 20189:44 amRNSDisposal of Interest in Global Pharm
11th Jul 201810:38 amRNSResult of General Meeting
28th Jun 20183:50 pmRNSPosting of Annual Report and Accounts
21st Jun 20187:00 amRNSAppointment of Broker
21st Jun 20187:00 amRNSFinal Results for the Year Ended 31 December 2017
15th Jun 20188:36 amRNSDisposal of Interest in Global Pharm & GM Notice
27th Apr 20187:00 amRNSUpdate on Disposal of Interest in Global Pharm
26th Apr 20181:57 pmRNSResult of General Meeting
20th Apr 20188:49 amRNSDirector/PDMR Shareholding
5th Apr 20183:54 pmRNSDisposal and Notice of General Meeting
29th Mar 20187:00 amRNSUpdate on Disposal of Interest in Global Pharm
26th Mar 20184:44 pmRNSIncreased Ownership in HKMH
19th Mar 20187:00 amRNSNew Investment
8th Feb 201812:17 pmRNSUpdate - Net Asset Value
2nd Feb 20188:24 amRNSDirector/PDMR Shareholding
15th Jan 20187:00 amRNSFurther re. Disposal of Interest in Global Pharm
21st Dec 20178:54 amRNSIncrease in Shareholding in Hong Kong Mining
31st Oct 201710:23 amRNSNet Asset Value Update
2nd Oct 20177:00 amRNSAppointment of Director
22nd Sep 20177:00 amRNSInterim Results For Six Months End 30 June 2017
20th Sep 201711:18 amRNSAGM and Share Consolidation
15th Sep 20177:00 amRNSDisposal of Interest in Global Pharm
30th Aug 20174:50 pmRNSProposed Share Consolidation
4th Aug 20173:36 pmRNSUpdate on Global Pharm Convertible Bond
27th Jul 20177:00 amRNSNet Asset Value(s)
20th Jul 20179:43 amRNSDirectorate Change
20th Jul 20179:27 amRNSAnnual General Meeting
3rd Jul 20179:14 amRNSAppointment of Director
29th Jun 201710:45 amRNSFinal Results
22nd Jun 20178:46 amRNSFurther Payment of Proceeds for TTS Disposal
15th Jun 20179:43 amRNSPayment of Proceeds for TTS Project Disposal
25th May 201711:06 amRNSResult of Meeting
2nd May 20177:00 amRNSChange of Investment Manager and Investing Policy
24th Feb 201711:45 amRNSUPDATE ON TTS PROJECT DISPOSAL
8th Feb 20179:26 amRNSUPDATE ON TTS PROJECT DISPOSAL
31st Jan 20177:00 amRNSDistribution from GCCF
23rd Jan 20179:15 amRNSUPDATE: REDEMPTION OF GLOBAL PHARM CONVERTIBLE
13th Jan 20178:15 amRNSUPDATE ON TTS PROJECT DISPOSAL
4th Jan 20179:00 amRNSProposed Disposal
29th Dec 20167:00 amRNSDirector/PDMR Shareholding
22nd Dec 20161:18 pmRNSDirector/PDMR Shareholding
20th Dec 20164:19 pmRNSDirector/PDMR Shareholding
13th Dec 20169:23 amRNSDirector/PDMR Shareholding
6th Dec 201612:34 pmRNSCorrection to Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.